Targeted Therapeutics Market Size, Share, and Trends 2026 to 2035

Revenue, 2025

USD 85.75 Bn

Forecast Year, 2035

USD 163.91 Bn

CAGR, 2026 - 2035

6.69%

Report Coverage

Global

What is the Targeted Therapeutics Market Size?

The global targeted therapeutics market size was calculated at USD 85.75 billion in 2025 and is predicted to increase from USD 91.76 billion in 2026 to approximately USD 163.91 billion by 2035, expanding at a CAGR of 6.69% from 2026 to 2035.

Targeted Therapeutics Market Key Takeaways

• North America led the global market with the highest market share in 2025.
• Asia-Pacific is estimated to expand at the fastest CAGR from 2026 to 2035.
• By Type, the monoclonal antibodies segment has held the biggest revenue share in 2025.
• By Type, the small molecule segment is anticipated to expand at the fastest CAGR during the projected period.
• By Application, the lung cancer segment held the highest market share in 2025.
• By Application, the breast cancer segment is projected to expand at the fastest CAGR over the projected period.
• By Distribution Channel, the hospital pharmacies segment had the largest market share in 2025.
• By Distribution Channel, the online pharmacies segment is anticipated to grow at the fastest CAGR over the projected period.

Targeted Therapeutics Market Growth Factors

The targeted therapeutics market is primarily driven by the growing burden of serious diseases such as cancer, leukemia, lymphoma, and muscular degeneration across the globe. The global cancer cases are predicted to grow by 47% from 2020 to 2040. It is anticipated that 28.4 million cases will be recorded in 2040, globally. Targeted therapeutics is a treatment that precisely uses drugs to target the cancer cells and prevents the normal cells from getting affected by the drugs. Furthermore, the rising awareness regarding the availability of targeted therapeutics among the population is boosting the growth of the global market. Rising investments towards the research activities for the protein and DNA changes that drives the cancer cells is expected to offer effective treatment through targeted therapeutics.

The cancer cells have a tendency to conceal itself from the human immune system. Therefore, the targeted therapeutics are proven effective to find such hidden cancer cells in the human body and treat those cells without affecting the normal cells. The rapid growth and popularity of the biologics has contributed towards the market growth. Increased investment in the field of biotechnology is propelling the growth of the global targeted therapeutics market. The monoclonal antibodies is one of the best selling drugs that emerged as a result of the rapid growth and development of the biologics industry. The targeted therapeutics is also effective in blocking the tumor cell proliferation. The targeted therapeutics market is boosted with the rising penetration of pharmacies across the globe. The rapidly growing online pharmacies is expected to foster the sales of the targeted therapeutic drugs in the upcoming years. Further, increasing government expenditure on the development of sophisticated healthcare infrastructure is another important factor that will play a crucial role in the growth of the global targeted therapeutics market.

Market Scope

Segment Insights

Type Insights

The monoclonal antibodies segment accounted largest revenue share in 2025. The monoclonal antibodies are the most effective drugs used in the treatment of various types of cancer. It is safer and has lower toxicity as compared to that of the traditional chemotherapy used in the cancer treatment. Therefore, the reduced side effect along with the effective treatment of cancer has boosted the growth of this segment.

The small molecule segment is expected to be the fastest-growing segment during the forecast period. The small molecule drugs are very much effective in targeting the specific cancer cells. The small molecule is getting traction in the developed markets for the treatment of malignancies. In 2022, the FDA approved around 89 anti-tumor small molecule drugs. Thus, this segment is expected to drive the growth of the targeted therapeutics market during the forecast period.

Application Insights

The lung cancer hit the largest revenue share in 2025 and is projected to sustain its dominance over the forecast period 2026 to 2035. This can be attributed to the increased cases of lung cancer and associated death across the globe. According to the International Agency for Research on Cancer, lung cancer was the leading cause of cancer deaths that accounted for around 18% of the global cancer deaths. Therefore, the increased demand for the treatment of lungs cancer has contributed significantly towards the growth of this segment.

The breast cancer is expected to be the fastest-growing segment during the forecast period. The breast cancer has become the most commonly diagnosed type of cancer, surpassing the lung cancer in 2025. The increasing cases of breast cancer among the global women population is expected to drive the growth of this segment.

Distribution Channel Insights

In 2025, The hospital pharmacies segment hit largest revenue share and is estimated to sustain its dominance during the forecast period. The increasing expenditure of the public and private organizations to develop the hospital infrastructure and supply the essential drugs to ensure it's availability in hospital pharmacies has boosted the segment's growth in the past years.

The online pharmacies is estimated to be the most opportunistic segment during the forecast period. The rapid penetration of internet, rapidly growing online pharmacies, and increasing adoption of smartphones are the several factors that are responsible for the growth of the online pharmacies segment across the globe.

Regional Insights

U.S. Targeted Therapeutics Market Size and Growth 2026 To 2035

The U.S. targeted therapeutics market size was evaluated at USD 22.86 billion in 2025 and is predicted to grow to around USD 44.00 billion by 2035, growing at a CAGR 6.77% between 2026 and 2035.

North America segment accounted for the largest revenue share in 2025 and is estimated to sustain its dominance during the forecast period. This can be attributed to the rapid growth of the biologics industry in North America. The availability of numerous biotechnology companies in the region has exponential contribution in the market growth. Further, rising investments coupled with the government's support to develop and expand the biopharmaceutical production facilities is expected to drive the targeted therapeutics market in North America.

The Asia Pacific is estimated to be the most opportunistic market during the forecast period. This is due to the rising consumer awareness regarding the availability of targeted therapeutics, rising prevalence of cancer and other chronic diseases, increasing disposable income, rising popularity of health insurance, and rapidly growing healthcare infrastructure. Moreover, the consumers have gained confidence regarding the safety and effectiveness of the targeted therapeutics owing to its ability to block the expansion of cancer cells with damaging the normal cells. This reduces the risk of side effects of cancer treatment.All these factors are expected to drive the market growth in the Asia Pacific region during the forecast period.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

In September 2020, Sanofi completed the acquisition of Principia Biopharma to strengthen its areas of allergic diseases and autoimmune diseases.

The various developmental strategies like acquisitions and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Targeted Therapeutics Market Companies

• Pfizer, Inc.
• AstraZeneca Plc.
• Amgen, Inc.
• F. Hoffmann-La Roche & Co.
• Genentech, Inc.
• Agenus, Inc.
• Celdara Medical LLC
• Arcus Biosciences, Inc.
• Aurinia Pharmaceuticals Inc.
• Gilead Sciences, Inc.
• Serena Therapeutics Inc.
• Nektar Therapeutics Inc.

Segments Covered in the Report

By Type

• Monoclonal Antibodies
• Small Molecule

By Application

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Renal Cancer
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Rest of the World